本文選題：咪唑安定 + 地佐辛　； 參考：《中國臨床藥理學雜志》2017年01期

【摘要】：目的觀察咪唑安定聯(lián)合地佐辛對圍術(shù)期胃腸道腫瘤患者的鎮(zhèn)痛療效及安全性。方法將74例胃腸道腫瘤患者隨機分為對照組37例與試驗組37例。對照組予以靜脈注射咪唑安定0.06 mg·kg~(-1)+芬太尼1.0μg·kg~(-1);試驗組予以靜脈注射咪唑安定0.06 mg·kg~(-1)+地佐辛0.1 mg·kg~(-1)。麻醉效果滿意后,由同一醫(yī)師完成胃腸道腫瘤根治術(shù)。比較2組患者的免疫功能、炎性因子,以及藥物不良反應的發(fā)生情況。結(jié)果術(shù)后4 h,試驗組和對照組的NK細胞百分比分別為(14.39±2.28)%,(12.99±1.84)%;CD_3~+分別為(52.94±4.19)%,(48.15±4.36)%;CD_4~+分別為(27.64±2.15)%,(24.71±2.08)%;CD_4~+/CD_8~+分別為(1.04±0.12),(0.96±0.15);白細胞介素-2(IL-2)分別為(72.92±8.32),(65.71±8.25)pg·mL~(-1);C反應蛋白分別為(48.26±9.14),(83.91±11.96)mg·L-1;腫瘤壞死因子-α分別為(26.81±6.30),(29.94±5.71)pg·mL~(-1);IL-6分別為(45.31±5.08),(66.95±7.13)pg·mL~(-1),差異均有統(tǒng)計學意義(P0.05)。試驗組和對照組輕度不適分別為8.11%(3/37例),27.03%(10/37例);呼吸抑制分別為10.81%(4/37例),62.16%(23/37例);惡心嘔吐發(fā)生率分別為5.41%(2/37例),35.14%(13/37例),差異均有統(tǒng)計學意義(P0.05)。試驗組和對照組完全性遺忘發(fā)生率分別為78.38%(29/37例),83.78%(31/37例),差異無統(tǒng)計學意義(P0.05)。結(jié)論咪唑安定聯(lián)合地佐辛方案與咪唑安定聯(lián)合芬太尼方案對圍術(shù)期胃腸道腫瘤患者的鎮(zhèn)痛療效相當,但前者能有效地促進患者術(shù)后免疫功能的恢復,控制炎癥反應,且安全性較好。
[Abstract]:Objective to observe the analgesic efficacy and safety of midazolam combined with dizosin in patients with gastrointestinal cancer during perioperative period. Methods 74 patients with gastrointestinal cancer were randomly divided into control group (n = 37) and trial group (n = 37). The control group was given intravenous injection of midazolam 0.06 mg / kg, fentanyl 1.0 渭 g / kg, and the experimental group was given 0.06 mg / kg / kg of midazolam and 0.1 mg / kg / kg of dizoxin, respectively. After the anesthetic effect was satisfied, the same doctor completed the radical operation of gastrointestinal cancer. The immune function, inflammatory factors and adverse drug reactions were compared between the two groups. 緇撴灉鏈悗4 h,璇曢獙緇勫拰瀵圭収緇勭殑NK緇嗚優(yōu)鐧懼垎姣斿垎鍒負(14.39鹵2.28)%,(12.99鹵1.84)%;CD_3~ 鍒嗗埆涓，

本文編號：1993161